US12617785B2 - Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss - Google Patents

Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Info

Publication number
US12617785B2
US12617785B2 US17/760,143 US202117760143A US12617785B2 US 12617785 B2 US12617785 B2 US 12617785B2 US 202117760143 A US202117760143 A US 202117760143A US 12617785 B2 US12617785 B2 US 12617785B2
Authority
US
United States
Prior art keywords
alkyl
mmol
ethyl
carbamate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/760,143
Other languages
English (en)
Other versions
US20230137893A1 (en
Inventor
Ksenia GNEDEVA
A. James HUDSPETH
Nathaniel KASTAN
Rui Liang
Peter T. Meinke
David John HUGGINS
Nigel John Liverton
Leigh Ashley BAXT
John David Ginn
Robert Walter MYERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Priority to US17/760,143 priority Critical patent/US12617785B2/en
Assigned to TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. reassignment TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: BAXT, Leigh Ashley, GINN, JOHN DAVID, HUGGINS, David John, LIANG, RUI, MEINKE, PETER T., MEYERS, ROBERT WALTER, LIVERTON, Nigel John
Assigned to THE ROCKEFELLER UNIVERSITY reassignment THE ROCKEFELLER UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Assigned to THE ROCKEFELLER UNIVERSITY reassignment THE ROCKEFELLER UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: KASTAN, Nathaniel, HUDSPETH, A. James, GNEDEVA, Ksenia
Assigned to TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. reassignment TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF INVENTOR ROBERT WALTER MEYERS TO ROBERT WALTER MYERS PREVIOUSLY RECORDED AT REEL: 061087 FRAME: 0686. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: BAXT, Leigh Ashley, GINN, JOHN DAVID, HUGGINS, David John, LIANG, RUI, MEINKE, PETER T., MYERS, ROBERT WALTER, LIVERTON, Nigel John
Publication of US20230137893A1 publication Critical patent/US20230137893A1/en
Application granted granted Critical
Publication of US12617785B2 publication Critical patent/US12617785B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US17/760,143 2020-02-05 2021-02-05 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss Active 2043-05-25 US12617785B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/760,143 US12617785B2 (en) 2020-02-05 2021-02-05 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970425P 2020-02-05 2020-02-05
PCT/US2021/016848 WO2021158936A1 (en) 2020-02-05 2021-02-05 Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
US17/760,143 US12617785B2 (en) 2020-02-05 2021-02-05 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Publications (2)

Publication Number Publication Date
US20230137893A1 US20230137893A1 (en) 2023-05-04
US12617785B2 true US12617785B2 (en) 2026-05-05

Family

ID=77199407

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/760,143 Active 2043-05-25 US12617785B2 (en) 2020-02-05 2021-02-05 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Country Status (9)

Country Link
US (1) US12617785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100008B1 (cg-RX-API-DMAC7.html)
JP (1) JP7678595B2 (cg-RX-API-DMAC7.html)
CN (1) CN115515579B (cg-RX-API-DMAC7.html)
AU (1) AU2021215925B2 (cg-RX-API-DMAC7.html)
CA (1) CA3170121A1 (cg-RX-API-DMAC7.html)
ES (1) ES3025983T3 (cg-RX-API-DMAC7.html)
MX (1) MX428671B (cg-RX-API-DMAC7.html)
WO (1) WO2021158936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515579B (zh) 2020-02-05 2025-09-30 洛克菲勒大学 吡咯并[2,3-b]吡啶-3-甲酰胺组合物和改善听力损失的方法
EP4380562A4 (en) * 2021-08-02 2025-05-21 The Rockefeller University PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELL PROLIFERATION
EP4687896A1 (en) * 2023-04-04 2026-02-11 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration
WO2026010871A1 (en) * 2024-07-01 2026-01-08 Hudspeth A James ((pyrrolopyridine-3-carbonyl) imino)-2,3-dihydrothiazol-4-yl) methyl phosphates for activating yap
KR20260029093A (ko) * 2024-08-23 2026-03-04 한국화학연구원 카이네이즈 억제제
WO2026043170A1 (ko) * 2024-08-23 2026-02-26 한국화학연구원 카이네이즈 억제제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129364A1 (en) 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
US20110082144A1 (en) 2003-11-24 2011-04-07 Transtech Pharma, Inc. N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US20110092538A1 (en) 2006-12-21 2011-04-21 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8592398B2 (en) 2010-12-20 2013-11-26 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as TRPA1 antagonists
WO2021158936A1 (en) 2020-02-05 2021-08-12 The Rockefeller University Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110082144A1 (en) 2003-11-24 2011-04-07 Transtech Pharma, Inc. N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US20070129364A1 (en) 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
US20110092538A1 (en) 2006-12-21 2011-04-21 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8592398B2 (en) 2010-12-20 2013-11-26 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as TRPA1 antagonists
WO2021158936A1 (en) 2020-02-05 2021-08-12 The Rockefeller University Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
American Chemical Society. Chemical Abstract Service. RN 1942057-09-1. Entered into STN: Jun. 29, 2016. (Year: 2016). *
International Search Report and Written Opinion in International Application No. PCT/US2021/016848 mailed Jul. 8, 2021.
Kastan et al. "Small-Molecule Inhibition of Lats Kinase Promotes Yap-dependent proliferation in Postmitotic Mammalian Tissues", bioRxiv, Apr. 16, 2020, pp. 1-42.
Pubchem CID 154857855, Create date: Dec. 15, 2020 (Dec. 15, 2020), entire document, especially p. 2, compound listed Dec. 15, 2020.
Pubchem SID: 438701942 deposited on Dec. 15, 2020, pp. 1-8. pg. 2.
Registry No. 1424635-83-5, CAS Registry Apr. 18, 2013.
U et al. "Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships" J. Med.Chem 52, 1701-1711(2009) 2009.
American Chemical Society. Chemical Abstract Service. RN 1942057-09-1. Entered into STN: Jun. 29, 2016. (Year: 2016). *
International Search Report and Written Opinion in International Application No. PCT/US2021/016848 mailed Jul. 8, 2021.
Kastan et al. "Small-Molecule Inhibition of Lats Kinase Promotes Yap-dependent proliferation in Postmitotic Mammalian Tissues", bioRxiv, Apr. 16, 2020, pp. 1-42.
Pubchem CID 154857855, Create date: Dec. 15, 2020 (Dec. 15, 2020), entire document, especially p. 2, compound listed Dec. 15, 2020.
Pubchem SID: 438701942 deposited on Dec. 15, 2020, pp. 1-8. pg. 2.
Registry No. 1424635-83-5, CAS Registry Apr. 18, 2013.
U et al. "Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships" J. Med.Chem 52, 1701-1711(2009) 2009.

Also Published As

Publication number Publication date
CA3170121A1 (en) 2021-08-12
AU2021215925B2 (en) 2026-04-09
JP2023512823A (ja) 2023-03-29
CN115515579B (zh) 2025-09-30
EP4100008A1 (en) 2022-12-14
CN115515579A (zh) 2022-12-23
US20230137893A1 (en) 2023-05-04
MX2022009572A (es) 2022-12-13
WO2021158936A1 (en) 2021-08-12
EP4100008A4 (en) 2024-02-07
ES3025983T3 (en) 2025-06-10
MX428671B (es) 2025-11-13
AU2021215925A1 (en) 2022-09-08
JP7678595B2 (ja) 2025-05-16
EP4100008B1 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
EP4100008B1 (en) Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
JP6728208B2 (ja) ベンザゼピンジカルボキサミド化合物
ES2893289T3 (es) Inhibidores de glucosidasa
US11731986B2 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US9181234B2 (en) Antibacterial compounds
US12534461B2 (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
US9346794B1 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
JP2019532995A (ja) タウタンパク質標的化protac、および関連使用方法
WO2018108156A1 (zh) Rock抑制剂及其应用
JP2007507549A (ja) キナーゼ阻害剤としての1,6,7−三置換アザベンゾイミダゾールの調製
US20180170906A1 (en) Therapeutic inhibitory compounds
US20080032991A1 (en) 2, 8-disubstituted Naphthyridine Derivatives
US20240343726A1 (en) Pyrrolopyridine-3- and 4-carboxamide compositions and methods for cellular proliferation
US11744824B2 (en) 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
JP2018503683A (ja) ピロールアミド系化合物、その製造方法、及び用途
KR20230129394A (ko) 리아노딘 수용체를 수반하는 장애를 치료하기 위한 작용제
CN102933214A (zh) 可用作二肽基肽酶-1(dpp-1)抑制剂的4,4-二取代的哌啶衍生物
HK40083035B (en) Parp7 inhibitor and use thereof
WO2025180442A1 (zh) Hdac抑制剂及其在医药上的应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUDSPETH, A. JAMES;KASTAN, NATHANIEL;GNEDEVA, KSENIA;AND OTHERS;SIGNING DATES FROM 20220520 TO 20220616;REEL/FRAME:061034/0332

Owner name: THE ROCKEFELLER UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUDSPETH, A. JAMES;KASTAN, NATHANIEL;GNEDEVA, KSENIA;AND OTHERS;SIGNING DATES FROM 20220520 TO 20220616;REEL/FRAME:061034/0332

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: THE ROCKEFELLER UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.;REEL/FRAME:060735/0477

Effective date: 20220726

Owner name: THE ROCKEFELLER UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GNEDEVA, KSENIA;HUDSPETH, A. JAMES;KASTAN, NATHANIEL;SIGNING DATES FROM 20220520 TO 20220616;REEL/FRAME:060735/0088

Owner name: TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIANG, RUI;MEINKE, PETER T.;HUGGINS, DAVID JOHN;AND OTHERS;SIGNING DATES FROM 20220527 TO 20220601;REEL/FRAME:061087/0686

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., NEW YORK

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF INVENTOR ROBERT WALTER MEYERS TO ROBERT WALTER MYERS PREVIOUSLY RECORDED AT REEL: 061087 FRAME: 0686. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:LIANG, RUI;MEINKE, PETER T.;HUGGINS, DAVID JOHN;AND OTHERS;SIGNING DATES FROM 20220527 TO 20220601;REEL/FRAME:061624/0277

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE